Background: The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension (PPH). Recently, fenfluramine appetite suppressants became widely ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

Dear K.T.: Dexfenfluramine, aka Redux (also called "fen-phen" in combination with phentermine), was sold in the 1990s until it was removed from the market in 1997 after valvular heart damage and ...

In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.

US-based pharmaceutical company MSD has reported that the Phase III ZENITH trial of WINREVAIR (sotatercept-csrk) for pulmonary arterial hypertension (PAH) met its primary endpoint. The double ...

A recent publication in the International Journal of Cardiology, Pulmonary artery denervation in pulmonary hypertension: A comprehensive ...

Main pulmonary artery diameter is a prognostic indicator in patients with pulmonary arterial hypertension without congenital heart disease.

The primary end point was a composite of death from any cause, lung transplantation, or hospitalization (≥24 hours) for worsening pulmonary arterial hypertension, assessed in a time-to-first ...

CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk ...

A recent publication by the British Thoracic Society offers the first long-term analysis of the UK Idiopathic Pulmonary ...

Not everybody with blockages needs surgical intervention. Guidelines recommend against surgery in people with no symptoms and less than 70% stenosis. Only when the blockage is greater than 70% is ...

Results from the Phase III ZENITH trial show that Winrevair lowered the risk of all-cause death, lung transplantation, and ...